argenex SE (NASDAQ:ARGX) Shares Acquired by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC boosted its holdings in shares of argenex SE (NASDAQ:ARGX - Free Report) by 0.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 125,295 shares of the company's stock after acquiring an additional 1,050 shares during the period. argenex accounts for approximately 1.2% of TimesSquare Capital Management LLC's investment portfolio, making the stock its 24th biggest position. TimesSquare Capital Management LLC owned about 0.21% of argenex worth $74,158,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of ARGX. FMR LLC grew its stake in argenex by 17.2% during the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock valued at $3,455,207,000 after acquiring an additional 824,750 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in argenex during the 4th quarter valued at about $91,013,000. GAMMA Investing LLC grew its stake in argenex by 53,684.9% during the 1st quarter. GAMMA Investing LLC now owns 135,538 shares of the company's stock valued at $802,200,000 after acquiring an additional 135,286 shares in the last quarter. Marshall Wace LLP grew its stake in argenex by 184.7% during the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company's stock valued at $117,805,000 after acquiring an additional 124,271 shares in the last quarter. Finally, Capital World Investors boosted its holdings in argenex by 5.1% in the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after purchasing an additional 86,687 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on ARGX. Wedbush reiterated an "outperform" rating and issued a $715.00 target price on shares of argenex in a report on Tuesday, June 24th. Oppenheimer boosted their target price on shares of argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Robert W. Baird upgraded shares of argenex from a "neutral" rating to an "outperform" rating and set a $680.00 target price on the stock in a report on Tuesday, May 13th. Baird R W upgraded shares of argenex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Finally, HC Wainwright restated a "buy" rating and issued a $720.00 price objective on shares of argenex in a report on Tuesday, July 1st. Nineteen investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, argenex has a consensus rating of "Buy" and a consensus price target of $728.06.

argenex Stock Down 1.3%

argenex stock traded down $7.45 during mid-day trading on Thursday, reaching $570.48. 271,717 shares of the company's stock were exchanged, compared to its average volume of 333,318. argenex SE has a twelve month low of $457.42 and a twelve month high of $678.21. The company has a fifty day moving average of $563.56 and a 200-day moving average of $600.69. The company has a market cap of $34.91 billion, a P/E ratio of 35.10, a P/E/G ratio of 1.01 and a beta of 0.37.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. argenex had a net margin of 40.20% and a return on equity of 16.15%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. Equities research analysts expect that argenex SE will post 3.13 earnings per share for the current fiscal year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.